New publication in Science Advances: TriPcides show promise against drug-resistant Staphylococcus aureus infections
May 20, 2026
In a new Science Advances publication, QureTech Bio co‑founders Fredrik Almqvist, Jörgen Johansson and Scott Hultgren report that TriPcides — a novel antibiotic class — can kill last‑resort‑resistant MRSA while suppressing key virulence factors, with no pre‑existing or emergent resistance observed.
QureTech Bio co-founders Fredrik Almqvist, Jörgen Johansson (Umeå University) and Scott Hultgren (Washington University, St. Louis), together with colleagues at their respective research groups and QureTech Bio researchers, have published a new study in Science Advances.
The study shows that TriPcides, a novel class of antibiotic compounds, can kill MRSA strains resistant to last-resort antibiotics — including dormant persister cells. No pre-existing resistance was detected across hundreds of clinical isolates, and no resistance emerged after prolonged exposure. TriPcides were also shown to suppress key virulence factors, reducing ulcer size and accelerating wound healing in infection models.
Read more:
Science Advances, DOI: 10.1126/sciadv.aec9100
About QureTech Bio
QureTech Bio AB is a biotechnology company focused on the development of novel therapeutics targeting infectious diseases and cancer. The company’s primary focus is the discovery and development of small‑molecule therapeutics directed at bacterial proteins implicated in cancer, as well as compounds effective against antibiotic‑resistant bacterial strains. QureTech Bio is located in Umeå, Sweden.